Q32 Bio Inc. $QTTB Shares Sold by Monaco Asset Management SAM

Monaco Asset Management SAM cut its holdings in shares of Q32 Bio Inc. (NASDAQ:QTTB) by 47.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 311,137 shares of the company’s stock after selling 280,800 shares during the period. Monaco Asset Management SAM owned 2.55% of Q32 Bio worth $616,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Marshall Wace LLP acquired a new position in Q32 Bio in the second quarter valued at $25,000. Acadian Asset Management LLC acquired a new position in Q32 Bio in the 1st quarter valued at about $50,000. AQR Capital Management LLC acquired a new stake in Q32 Bio during the 1st quarter worth approximately $68,000. Jane Street Group LLC acquired a new stake in Q32 Bio during the 2nd quarter worth approximately $69,000. Finally, Goldman Sachs Group Inc. raised its stake in shares of Q32 Bio by 140.9% during the first quarter. Goldman Sachs Group Inc. now owns 44,373 shares of the company’s stock worth $73,000 after purchasing an additional 25,953 shares during the last quarter. Hedge funds and other institutional investors own 31.32% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on QTTB shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Q32 Bio in a research note on Friday, January 9th. Wall Street Zen upgraded Q32 Bio from a “sell” rating to a “hold” rating in a research note on Sunday, October 26th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Reduce” and an average price target of $15.00.

Q32 Bio Price Performance

Shares of NASDAQ:QTTB opened at $4.69 on Friday. The business’s 50 day simple moving average is $3.65 and its 200-day simple moving average is $2.80. The firm has a market capitalization of $57.69 million, a price-to-earnings ratio of -1.36 and a beta of 0.16. Q32 Bio Inc. has a 12 month low of $1.35 and a 12 month high of $6.37.

Insider Transactions at Q32 Bio

In other Q32 Bio news, CEO Jodie Pope Morrison sold 22,506 shares of Q32 Bio stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $3.46, for a total transaction of $77,870.76. Following the completion of the transaction, the chief executive officer owned 99,000 shares in the company, valued at approximately $342,540. The trade was a 18.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Lee Kalowski sold 9,072 shares of the company’s stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $3.46, for a total transaction of $31,389.12. Following the completion of the sale, the chief financial officer directly owned 39,938 shares in the company, valued at $138,185.48. This trade represents a 18.51% decrease in their position. The SEC filing for this sale provides additional information. 40.00% of the stock is currently owned by corporate insiders.

Q32 Bio Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.